Name:	anip_AcquisitionCostsCapitalized
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The expensed costs incurred in an acquisition, including recording fees, legal costs, and other costs incurred in acquiring assets.

No definition available.

Name:	anip_AcquisitionCostsExpensed
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Active pharmaceutical ingredients acquired in an asset acquisition.

No definition available.

Name:	anip_ActivePharmaceuticalIngredientsAcquiredInAssetAcquition
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Net amount of increase to finite lived intangible assets after impact of cumulative amortization expense.

No definition available.

Name:	anip_AdditionalNetCarryingValueAddedToFiniteLivedIntangibleAssetsAcquired
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of inventory recognized as of the acquisition date.

No definition available.

Name:	anip_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Represents contingent consideration related to an asset purchase.

No definition available.

Name:	anip_ContingentConsiderationInAnAssetPurchase
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents a contingent liability that has not been recognized because it is not both estimable and probable.

No definition available.

Name:	anip_ContingentLiabilityNotRecognized
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Contingent liability recognized in an asset acquisition.

No definition available.

Name:	anip_ContingentLiabilityRecognized
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Represents cumulative amortization expense related to transaction.

No definition available.

Name:	anip_CumulativeAmortizationExpense
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

No definition available.

Name:	anip_FairValuesInputsDiscountRate
Namespace Prefix:	anip_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Finished goods acquired in an asset acquisition.

No definition available.

Name:	anip_FinishedGoodsAcquiredInAssetAcquisition
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Represents the number of approved products under product portfolio.

No definition available.

Name:	anip_NumberOfApprovedProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the number of approved products with launches pending under product portfolio.

No definition available.

Name:	anip_NumberOfApprovedProductsWithLaunchesPendingUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the number of commercial products under product portfolio.

No definition available.

Name:	anip_NumberOfCommercialProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the number of filed products under product portfolio.

No definition available.

Name:	anip_NumberOfFiledProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of generic drug products.

No definition available.

Name:	anip_NumberOfGenericDrugProducts
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Number of drug product acquired in an asset purchase.

No definition available.

Name:	anip_NumberOfGenericDrugProductsAcquired
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the number of in-development products under product portfolio.

No definition available.

Name:	anip_NumberOfInDevelopmentProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

The number of years for the amount payable on the contingent profit share.

No definition available.

Name:	anip_NumberOfYearsContingentProfitSharePayable
Namespace Prefix:	anip_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Name:	us-gaap_DebtInstrumentCarryingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Nominal or face amount used to calculate payments on the derivative asset.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959

Name:	us-gaap_DerivativeAssetNotionalAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	na
Period Type:	instant

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266

Name:	us-gaap_GoodwillImpairmentLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.

No definition available.

Name:	us-gaap_InterestRateDerivativeLiabilitiesAtFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Name:	us-gaap_InventoryFinishedGoods
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Name:	us-gaap_InventoryRawMaterials
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

No definition available.

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Name:	srt_CounterpartyNameAxis=anip_AppcoPharmaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_CounterpartyNameAxis=anip_PharmaceuticsInternationalIncAndBasAndaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CreditFacilityAxis=anip_SeniorSecuredCreditFacilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_LineOfCreditFacilityAxis=anip_DelayedDrawTermLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=anip_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BusinessAcquisitionAxis=anip_IDTAustraliaLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=anip_AbbreviatedNewDrugApplicationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=anip_AcquiredNewDrugApplicationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BusinessAcquisitionAxis=anip_ImpaxLaboratoriesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CollateralAxis=us-gaap_EquipmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	srt_ProductOrServiceAxis=anip_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BusinessAcquisitionAxis=anip_AmerigenPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=anip_TevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	dei_LegalEntityAxis=anip_CoeptisPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: